Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • APX3330
    • APX2009
    • Phentolamine Ophthalmic Solution 0.75%
    • Scientific Posters and Publications
  • Clinical Trials
    • Overview
    • VEGA-2 Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution 0.75% in Presbyopia Enrolling
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

Read Press Release

Ocuphire in the News

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

VIDEO: Surgeon summarizes award-winning abstract presentation on DR treatment

Aug 29, 2023

WIO 2023: ZETA-1 phase 2 trial safety and tolerability results for APX3330

Aug 26, 2023

ASRS 2023: ZETA-1 phase 2 trial efficacy results for APX3330 with David Lally, MD

Aug 9, 2023

VIDEO: Ocuphire to discuss APX3330 outcome measure with FDA

Aug 8, 2023

David Lally, MD: Efficacy of Oral APX3330 for Diabetic Retinopathy

Aug 6, 2023

ON THE HORIZON: DIABETIC RETINOPATHY TREATMENTS — WITHOUT INJECTIONS

Jul 1, 2023

Phase 2 ZETA-1 Trial Suggests Promise of APX3330 in Diabetic Retinopathy

Jun 27, 2023

Shrinking Night Vision Disturbances

Jun 1, 2023

Phentolamine (Nyxol) Clinical Trials Next in the Pipeline for Presbyopia

Apr 27, 2023

Potential Wide Use for Ocuphire’s APX-3330: An Oral Drug to Prevent Diabetic Retinopathy Progression—Results of the Phase 2 ZETA-1 Trial

Mar 23, 2023
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »
Ocuphire Pharma, Inc.
© Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use